Literature DB >> 21393440

Acute myeloid leukemia.

Margaret R O'Donnell1, Camille N Abboud, Jessica Altman, Frederick R Appelbaum, Steven E Coutre, Lloyd E Damon, James M Foran, Salil Goorha, Lori J Maness, Guido Marcucci, Peter Maslak, Michael M Millenson, Joseph O Moore, Farhad Ravandi, Paul J Shami, B Douglas Smith, Richard M Stone, Stephen A Strickland, Martin S Tallman, Eunice S Wang.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21393440     DOI： 10.6004/jnccn.2011.0027

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  17 in total

1.  Haematological cancer: The rule of three in AML induction--is cladribine the answer?

Authors:  Frederick R Appelbaum
Journal:  Nat Rev Clin Oncol       Date:  2012-06-19       Impact factor: 66.675

2.  Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.

Authors:  Deepa Sampath; Asifa Malik; William Plunkett; Billie Nowak; Betsy Williams; Michelle Burton; Srdan Verstovsek; Stefan Faderl; Guillermo Garcia-Manero; Alan F List; Said Sebti; Hagop M Kantarjian; Farhad Ravandi; Jeffrey E Lancet
Journal:  Leuk Res       Date:  2013-08-06       Impact factor: 3.156

3.  Automated decision tree to evaluate genetic abnormalities when determining prognostic risk in acute myeloid leukemia.

Authors:  Kevin Watanabe-Smith; Brian J Druker; Jeffrey W Tyner; David K Edwards
Journal:  Haematologica       Date:  2018-03-22       Impact factor: 9.941

4.  Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.

Authors:  Michael S Mathisen; Hagop Kantarjian; Elias Jabbour; Guillermo Garcia-Manero; Farhad Ravandi; Stefan Faderl; Gautam Borthakur; Jorge E Cortes; Alfonso Quintás-Cardama
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-12-29

5.  Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes.

Authors:  Alexander E Sherman; Gabriela Motyckova; K Rebecca Fega; Daniel J Deangelo; Gregory A Abel; David Steensma; Martha Wadleigh; Richard M Stone; Jane A Driver
Journal:  Leuk Res       Date:  2013-06-06       Impact factor: 3.156

6.  Normal karyotype mosaicism in adult AML patients with adverse-risk and undefined karyotype: preliminary report of treatment outcomes after hematopoietic stem cell transplantation.

Authors:  Jae-Ho Yoon; Hee-Je Kim; Seung-Hwan Shin; Seung-Ah Yahng; Byung-Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Seok Lee; Chang-Ki Min; Seok-Goo Cho; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Chong-Won Park
Journal:  Int J Hematol       Date:  2013-04-25       Impact factor: 2.490

7.  NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.

Authors:  Sophia Adamia; Michal Bar-Natan; Benjamin Haibe-Kains; Patrick M Pilarski; Christian Bach; Samuel Pevzner; Teresa Calimeri; Herve Avet-Loiseau; Laurence Lode; Sigitas Verselis; Edward A Fox; Ilene Galinsky; Steven Mathews; Ibiayi Dagogo-Jack; Martha Wadleigh; David P Steensma; Gabriela Motyckova; Daniel J Deangelo; John Quackenbush; Daniel G Tenen; Richard M Stone; James D Griffin
Journal:  Blood       Date:  2014-02-26       Impact factor: 22.113

8.  A 75-year-old woman with thoracic spinal cord compression and chloroma (granulocytic sarcoma).

Authors:  Madhava Baikaidi; Stephen S Chung; Martin S Tallman; Lloyd E Damon; Alison R Walker; Guido Marcucci; Abdalla M Sholi; Gloria J Morris
Journal:  Semin Oncol       Date:  2012-12       Impact factor: 4.929

9.  Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.

Authors:  Aziz Nazha; Hagop Kantarjian; Farhad Ravandi; Xuelin Huang; Sangbum Choi; Guillermo Garcia-Manero; Elias Jabbour; Gautam Borthakur; Tapan Kadia; Marina Konopleva; Jorge Cortes; Alessandra Ferrajoli; Steve Kornblau; Naval Daver; Naveen Pemmaraju; Michael Andreeff; Zeev Estrov; Min Du; Mark Brandt; Stefan Faderl
Journal:  Am J Hematol       Date:  2013-09-09       Impact factor: 10.047

10.  The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.

Authors:  Cedric Dos Santos; Tinisha McDonald; Yin Wei Ho; Hongjun Liu; Allen Lin; Stephen J Forman; Ya-Huei Kuo; Ravi Bhatia
Journal:  Blood       Date:  2013-07-29       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.